Finanzas de Vivos Therapeutics Inc (VVOS)VVOSVivos Therapeutics Inc

Vivos Therapeutics Inc (VVOS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Appliance sales to integrated providers, accounting for 26.9% of total sales, equivalent to $1.03M. Other significant revenue streams include Center revenue and Sleep testing services. Understanding this composition is critical for investors evaluating how VVOS navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Vivos Therapeutics Inc maintains a gross margin of 47.41%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -93.63%, while the net margin is -107.18%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively VVOS converts its operational activities into shareholder value.

In the context of the broader market, VVOS competes directly with industry leaders such as BIAF and WOK. With a market capitalization of $2.87M, it holds a significant position in the sector. When comparing efficiency, VVOS's gross margin of 47.41% stands against BIAF's 23.91% and WOK's 19.14%. Such benchmarking helps identify whether Vivos Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Vivos Therapeutics has shown significant revenue growth, with Q2 2026 revenue at $5.2 million, a 35% increase year-over-year. However, the net loss has widened to $5.5 million, reflecting ongoing financial challenges. Gross margin improved to 57%, but the overall financial health remains concerning.